Chairman & CEO
Safe, quality generic products start with strong leadership.
Chairman & CEO
Chief Strategic Officer
Chief Scientific Officer
President, Manufacturing Services
Chief Operating Officer
Chief Financial Officer
Executive Vice President
Vice President of Operations
Senior Vice President of Scientific Affairs
As Chairman & CEO of Ingenus Pharmaceuticals, Mr. Mantena is a career innovator responsible for providing overall leadership and strategic direction for the business. Prior to creating Ingenus Pharmaceuticals, he founded ICORE Healthcare, a company that provides health plans with solutions to manage specialty cost trends. Prior to ICORE, he founded International Oncology Network (ION), an oncology group purchasing organization, and OncoScripts, one of the first oncology focused specialty pharmacies.
Mr. Mantena earned his degree in clinical pharmacy from the University of Maryland and a bachelor’s degree in computer science and engineering from JNTU (Jawaharlal Nehru Technological University) in India.
As President of Ingenus Pharmaceuticals, Mr. Gellman is responsible for providing leadership and tactical direction for the company. Prior to creating Ingenus, Mr. Gellman was the chief operating officer for ICORE Healthcare, a specialty drug management company focused on managing specialty drug spend for Payors. Previously, Mr. Gellman served as the President/GM of Integrated Commercialization Solutions (ICS), a third party logistics provider to the pharmaceutical industry.
Mr. Gellman holds a bachelor’s degree in business administration from the University of Michigan.
Mr. Valiveti has over 20 years of experience in pharmaceutical manufacturing and retail pharmacies. Before coming to the U.S., he held a position as a principal at the PES College of Pharmacy, India. He was instrumental in starting the college and making it into one of the country’s best and most-trusted colleges at the young age of 24 years. He also worked at Lederle Labs, the generic division of Wyeth Pharmaceuticals, for over two years in the manufacturing, analytical method development, quality control and release. Mr. Valiveti is a successful businessperson with an interest in the entire pharmaceutical landscape covering API, product development, manufacturing, distribution, GPO, and retail pharmacies.
Mr. Valiveti holds a Master of Science degree in Pharmaceutical Sciences and is a registered pharmacist.
Mr. Gande has over 20 years of proven experience in pharmaceutical formulation R & D, API sourcing, bio-Studies/clinical studies and regulatory submissions. He has successfully identified, developed and commercialized over 100 generic products for the U.S. markets. A successful serial entrepreneur, Mr. Gande has co-founded five successful pharmaceutical business ventures. These include CorePharma, a generic pharmaceutical company in Middlesex, New Jersey; Synerx Pharma, a specialty injectable company in Newton, Pennsylvania; Apicore, a specialty API development and manufacturing company in Somerset, New Jersey and Gujarat, India; RiconPharma, a specialty pharmaceutical company in Denville, New Jersey and India; and Mirror Pharmaceuticals, a pharmaceutical development and manufacturing company in Fairfield, New Jersey.
Mr. Gande holds a Master of Science degree in Pharmaceutical Sciences and is a registered pharmacist.
Mr. Devalapalli has over 25-years of experience in pharmaceutical product and process development, product enhancement, lifecycle management, scale-up, technology transfer, validation, manufacturing, quality management and regulatory compliance. He has held key positions in companies such as Pfizer, Warner-Lambert, Becton Dickinson Transdermal Research, and Penwest Pharmaceuticals.
Mr. Devalapalli has an MS degree in Industrial Pharmacy/Pharmaceutics and an MBA in Pharmaceutical Business. He is also a registered pharmacist in the state of New Jersey.
As COO of Ingenus, Dr. Mehta is responsible for strategic and operational leadership for the growth of the company. Prior to joining Ingenus, Dr. Mehta was the President of Accord Healthcare, USA where he was responsible for the company’s inception, growth and management. Dr. Mehta brings over 16 years of pharmaceutical experience in overseeing such diverse areas as Hatch Waxman litigation, generic pharmaceutical sales, and marketing and pharmaceutical product development and registration.
Dr. Mehta earned his PhD in Pharmaceutical Sciences from the University of Georgia.
As the CFO for Ingenus Pharmaceuticals, Mr. Baumgartner is responsible for the financial regulations of the company. Mr. Baumgartner has an extensive background in organizational and operational management, financial structures and M&A. He began his professional career in public accounting with Peat Marwick (later KPMG). Throughout his career, Mr. Baumgartner has worked in multiple industries including healthcare, finance, and manufacturing.
Mr. Dutra brings to Ingenus twenty-plus years in the pharmaceutical industry, with the majority of those years spent starting and building-out smaller generic companies. In his last position, Mr. Dutra was the Executive Vice President of North American Generics for Glenmark Pharmaceuticals. During his ten-plus years at Glenmark Pharmaceuticals, Mr. Dutra was instrumental in the formation and tremendous growth of the organization. He was responsible for sales and marketing, contracting, customer service, supply chain, and warehouse and distribution. Prior to Glenmark, Mr. Dutra was the Director of Sales and Marketing for Dr. Reddy’s Laboratories. There, his responsibilities included building the commercialization platform for the company’s robust pipeline of products.
Mr. Dutra’s strong business acumen, abundant industry knowledge, and extensive contacts are a perfect match to propel Ingenus to the forefront of innovation within the generic industry.
As Vice President of Operations for Ingenus Pharmaceuticals, Ms. Dunk is responsible for the overall Operations of the business, which includes customer service, warehousing and distribution, supply chain management, marketing, account management, pharmacovigilance, contracts and chargeback administration, government pricing and Medicaid administration. Ms. Dunk has over 20 years of experience in the pharmaceutical industry, starting her career at Barre-National (Alpharma). She later and worked for Geneva Pharmaceuticals, ENDO Pharmaceuticals, Dr. Reddy’s Laboratories, and Wockhardt USA.
Ms. Dunk holds a bachelor’s degree in computer science from Loyola College in Baltimore, Maryland.
Dr. Billa has a PhD in Pharmaceutics with over 20 years of proven experience in pre-formulations, analytical R&D, formulation development, bio-studies, and regulatory submissions. He held key positions in pharmaceutical R & D at Wockhardt, Reddy’s Laboratories and Orchid Pharma, Ltd. Dr. Billa was instrumental in developing over 100 ANDA’s and managed over 20 Paragraph IV challenges. He has developed several complex dosage forms, modified release tablets and capsules, suspensions and lyophilized injectables, and has developed over 30 Injectable ANDA products, which involved PENAMS and Cephalosporins. Dr. Billa has significant experience in solid oral dosages (IR and MR), topicals, liquids, and parenterals, and holds has several patents (U.S. and WO) and publications.